CLLS
Price
$1.58
Change
-$0.07 (-4.24%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
150.58M
28 days until earnings call
MDGL
Price
$298.87
Change
-$1.28 (-0.43%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
6.66B
34 days until earnings call
Interact to see
Advertisement

CLLS vs MDGL

Header iconCLLS vs MDGL Comparison
Open Charts CLLS vs MDGLBanner chart's image
Cellectis SA
Price$1.58
Change-$0.07 (-4.24%)
Volume$226
Capitalization150.58M
Madrigal Pharmaceuticals
Price$298.87
Change-$1.28 (-0.43%)
Volume$9.57K
Capitalization6.66B
CLLS vs MDGL Comparison Chart in %
Loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLLS vs. MDGL commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Buy and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (CLLS: $1.65 vs. MDGL: $300.15)
Brand notoriety: CLLS and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLLS: 197% vs. MDGL: 106%
Market capitalization -- CLLS: $150.58M vs. MDGL: $6.66B
CLLS [@Biotechnology] is valued at $150.58M. MDGL’s [@Biotechnology] market capitalization is $6.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLLS’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • CLLS’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than CLLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • CLLS’s TA Score: 5 bullish, 5 bearish.
  • MDGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than CLLS.

Price Growth

CLLS (@Biotechnology) experienced а +10.00% price change this week, while MDGL (@Biotechnology) price change was +8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

CLLS is expected to report earnings on Jul 31, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.66B) has a higher market cap than CLLS($151M). MDGL YTD gains are higher at: -2.729 vs. CLLS (-8.333). CLLS has higher annual earnings (EBITDA): -32.49M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. CLLS (242M). CLLS has less debt than MDGL: CLLS (91.8M) vs MDGL (120M). MDGL has higher revenues than CLLS: MDGL (317M) vs CLLS (47.6M).
CLLSMDGLCLLS / MDGL
Capitalization151M6.66B2%
EBITDA-32.49M-376.15M9%
Gain YTD-8.333-2.729305%
P/E RatioN/AN/A-
Revenue47.6M317M15%
Total Cash242M843M29%
Total Debt91.8M120M77%
FUNDAMENTALS RATINGS
CLLS vs MDGL: Fundamental Ratings
CLLS
MDGL
OUTLOOK RATING
1..100
158
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5355
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLLS's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for MDGL (64) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for CLLS (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CLLS’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as CLLS (97) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CLLS’s over the last 12 months.

CLLS's Price Growth Rating (53) in the Biotechnology industry is in the same range as MDGL (55) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

CLLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLLSMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BNXTF0.400.05
+14.61%
BIONXT SOLUTIONS INC.
PRDSY12.600.10
+0.80%
Prada Spa
OJIPF5.09N/A
N/A
Oji Holdings Corp
AUCTF8.96N/A
N/A
Aucnet Inc
OMTK0.01-0.01
-42.11%
Omnitek Engineering Corp.